Do you want to know how reliable your data are?
PAASP is a global leader in the assessment and accreditation of nonclinical research practice in the field of life sciences. We provide services to facilitate the generation of robust and reliable data and enable improved and accelerated decision-making. Our mission is to increase the probability that basic nonclinical discoveries will translate into safe and effective clinical treatments.
Risks in early-stage biotech investment
As the recent cases illustrate, apparent or actual issues with data integrity and research rigor can damage not only reputation of individual scientists but also affect the value of companies, whether privately held or publicly traded.
PAASP introduces a new service for the investment community engaged in early-stage biotech:
PAASPort®-based assessment of investment opportunities for data integrity and research rigor risks.
PAASP NETWORK PARTNERS ARE SUPPORTED BY
A taste of our most recent headlines.
Don’t throw the baby out with the bathwaterDecember 22, 2023
The pressure to replace animal research with non-animal methods is growing. Earlier this year, NIH has issued a “Request for Information…Read More
“Home inspections” for life sciences companies going public before clinical proof of conceptDecember 22, 2023
For over a decade, there is a trend of less specialized investment firms and public equity investors betting on life sciences…Read More
Additional Reads in December 2023December 22, 2023
Further commentaries, articles and blog posts worth reading:Zen und die Kunst, Forschung zu bewerten (in German) In defense of quantitative metrics…Read More